Posts by: Patricia Inacio, PhD

Patricia Inacio, PhD

Patricia holds her Ph.D. in Cell Biology from University Nova de Lisboa, and has served as an author on several research projects and fellowships, as well as major grant applications for European Agencies. She also served as a PhD student research assistant in the Laboratory of Doctor David A. Fidock, Department of Microbiology & Immunology, Columbia University, New York.

February 28, 2019February 28, 2019

First Patient Enrolled in Phase 1/2 Trial Testing CTX001 for Severe Sickle Cell Disease

News

A Phase 1/2 clinical trial evaluating investigational therapy CTX001 for severe sickle cell disease (SCD) has enrolled its first patient in the U.S., and treatment is expected to begin by mid-2019. The ... Read more

January 22, 2019January 22, 2019

Safety and Early Hints of Benefit Seen in Phase 1b Trial of PF-04447943

News

Sickle cell disease (SCD) patients were safely treated with a phosphodiesterase 9A (PDE9) inhibitor therapy called PF-04447943 with no serious side effects reported and possible evidence of fewer vaso-occlusion ... Read more

January 7, 2019January 8, 2019

CTX001 Earns FDA’s Fast Track Status for Treating Sickle Cell Disease

News

The U.S. Food and Drug Administration (FDA) has awarded fast track status to investigational therapy CTX001 to treat sickle cell disease. A Phase 1/2 clinical trial (NCT03745287) is recruiting patients. CTX001 uses the CRISPR gene-editing technology ... Read more

April 19, 2018April 19, 2018

Sickle Cell Disease Researchers Identify a Children’s Stroke Prediction Tool

News

The amount of oxygen the blood loses when traveling through the brain could help identify children with sickle cell disease who are at risk of having a stroke, a ... Read more

March 27, 2018March 27, 2018

Sickle Cell Patients at Higher Risk for ER Readmission, Hospitalization, Study Finds

News

Patients with sickle cell disease show the highest rates of readmission and hospitalization within 30 days of being discharged from an emergency department, a single-center study found. The study, ... Read more

February 15, 2018February 15, 2018

Imara Begins Phase 2 Sickle Cell Disease Trial Testing IMR-687 in Adults

News

Imara, a pharmaceutical company developing new therapies for sickle cell disease (SCD), has successfully dosed the first patient enrolled in its clinical trial evaluating escalating doses of IMR-687 in ... Read more

February 8, 2018February 8, 2018

Hypersensitivity to Allergens May Increase Risk of Acute Chest Syndrome in Sickle Cell Anemia Children

News

Hypersensitivity to allergens in children with sickle cell anemia may increase the risk of acute chest syndrome, a study suggests. The study “Aeroallergen sensitization predicts acute chest syndrome in children ... Read more

January 9, 2018January 9, 2018

Bluebird Bio Presents Positive Early Results of Gene Therapy LentiGlobin for Sickle Cell Disease

News

Bluebird bio announced encouraging interim results from the ongoing Phase 1 clinical trial testing its investigational gene therapy LentiGlobin for patients with severe sickle cell disease (SCD). The results were ... Read more

November 28, 2017November 28, 2017

Expert Analysis Updates Advice on Managing Sickle Cell Retinopathy

News

Following a review of studies published in the last decade, experts have updated their recommendations for managing a sickle cell disease-related eye complication known as sickle cell retinopathy (SCR). ... Read more

November 7, 2017November 7, 2017

Investigational Therapy Altemia Achieves Main Endpoints in Pediatric Sickle Cell Trial

News

Sancilio Pharmaceuticals says its investigational therapy Altemia (SC411) achieved primary and secondary endpoints in a clinical trial with sickle cell patients 5 to 17 years old. Altemia is a combination ... Read more

Pin It on Pinterest